BridgeBio Pharma (BBIO) Work In Process (2025 - 2026)
BridgeBio Pharma (BBIO) posted Work In Process of $10.5 million for Q1 2026, up 71.77% sequentially from $6.1 million in Q4 2025, and up 695.52% YoY from $1.3 million in Q1 2025.
BridgeBio Pharma (BBIO) Work In Process (2025 - 2026) Analysis & Trends
BridgeBio Pharma has reported Work In Process for 2 years, with the latest figure at $10.5 million in Q1 2026.
- Quarterly Work In Process rose 695.52% year-over-year to $10.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.5 million (up 695.52% YoY) and the FY2025 annual result came in at $6.1 million, changed N/A from the prior year.
- Work In Process improved to $10.5 million in Q1 2026 per BBIO's latest filing, from $6.1 million in the prior quarter.
- Over five years, Work In Process peaked at $10.5 million in Q1 2026 and troughed at $1.1 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | BridgeBio Pharma | 15.60 Bn | 14.89 Bn | 228.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.70 Mn |
| Mar 31, 2026 | 10.49 Mn |
| Dec 31, 2025 | 6.10 Mn |
| Sep 30, 2025 | 4.13 Mn |
| Jun 30, 2025 | 1.07 Mn |
| Mar 31, 2025 | 1.32 Mn |